OU Internal Medicine Residency

📊 Key takeaways: • Evolocumab ↓ first MACE vs placebo in high-risk ASCVD or diabetes patients without prior MI/stroke • ~55% ↓ LDL-C on top of statins, supporting primary prevention benefit • Future focus: cost-effectiveness & clinical integration

PICO: 👥 P: ASCVD or diabetes, no prior MI/stroke 💊 I: Evolocumab + standard lipid therapy ⚖️ C: Placebo + standard therapy 📉 O: ↓ LDL-C & ↓ first MACE

📌 Journal Club – Feb 16, 2026 Topic: What is the effect of evolocumab as primary prevention for patients with ASCVD or diabetes without prior MI or stroke? #ASCVD #DiabetesCare #PrimaryPrevention #Evolocumab #LipidManagement #PreventiveCardiology #ClinicalResearch

PICO: P: Cirrhosis with upper GI bleeding I: Prophylactic antibiotics C: Shorter duration or no antibiotics O: Infection, mortality, clinical outcomes #JournalClub #GI #Cirrhosis #AntibioticStewardship #EvidenceBasedMedicine

🔍Key takeaways: • Class I recs rely on low–moderate quality evidence • Shorter/no antibiotics trend toward non-inferiority • Heterogeneous infection definitions limit conclusions ➡️ Not practice-changing—high-quality RCTs needed

📚 Journal Club Discussion - January 19th, 2026 💊 Do all patients with cirrhosis + UGIB need prophylactic antibiotics? 📄 Prophylactic Antibiotics for Upper GI Bleeding in Cirrhosis 📰 JAMA Internal Medicine

🎉 HUGE congratulations to our incredible residents on a 100% fellowship match rate! 🎉 We are so proud of all you’ve accomplished and can’t wait to see you continue to excel in fellowship and beyond. The future is bright! ✨ 📸 Fellowship Match Day photos are posted below!

📊 Method & practice insight: Using a larger non-inferiority margin (10%) due to early termination, SABATO isn’t paradigm-shifting; but it supports earlier discharge and reduced IV exposure for carefully selected patients with close ID oversight. #DOMJournalClub #MedTwitter

✅ Primary result & clinical takeaway: Early oral switch therapy was non-inferior to continued IV therapy in carefully selected, low-risk patients, supporting oral step-down as a reasonable option for uncomplicated MSSA bacteremia after appropriate IV lead-in 🔍.

📚This Week’s DOM Journal Club Discussing the SABATO trial (The Lancet Infectious Diseases): Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection. #DOMJournalClub #MedTwitter

💡 Why It Matters This study provides strong evidence supporting early corticosteroid therapy as part of ICU management for severe CAP; showing both survival benefits and improved clinical stability.

🔑 Key Takeaways 1️⃣ Trial ended early (COVID); 795 analyzed 2️⃣ Steroids ↓28-day mortality (6.2% vs 11.9%) 3️⃣ ↓Intubation + ↓vasopressor use 4️⃣ No major safety differences 5️⃣ Overall: Steroids improved outcomes in severe CAP

📚 Journal Club with Dr. Astani 📘 Article: Hydrocortisone in Severe Community-Acquired Pneumonia — The New England Journal of Medicine This week, we dug into a key RCT examining IV hydrocortisone for ICU patients with severe CAP. Here’s the quick breakdown ⬇️